Randomized, Placebo-controlled, Double-blind, Parallel Group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses (10 - 1500 mg, Tablets) of BAY1817080 Including the Effect of Food and Itraconazole on the Relative Bioavailability of BAY1817080 in Healthy Men
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Aug 2017
At a glance
- Drugs BAY 1817080 (Primary) ; Itraconazole
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Bayer
- 01 Aug 2017 Planned End Date changed from 21 Jul 2017 to 23 Aug 2017.
- 09 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Mar 2017 Planned number of patients changed from 65 to 89.